shingles

Mark Butler made his comments in light of Novavax withdrawing its application from TGA registration in Australia.

Since the vaccine stimulates the immune system, it may cause the body to target viral-related remnants in the eye, leading to a recurrence of ocular shingles.

Up to 30 percent of people in the United States will develop shingles in their lifetime, and the risk of developing it increases as we age.